Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor

NCT02261207 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Solitary Fibrous Tumor

Interventions

DRUG: Axitinib

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano